Full Text | PDF

Theranostics 2019; 9(25):7889-7905. doi:10.7150/thno.38583 This issue Cite

Review

Advances in Engineering Cells for Cancer Immunotherapy

Xiao Xu^1#, Teng Li^1#, Shiyang Shen¹, Jinqiang Wang^2,3, Peter Abdou^2,3, Zhen Gu^2,3✉, Ran Mo^1✉

1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China.
2. Department of Bioengineering, University of California, Los Angeles, CA 90095, USA.
3. Jonsson Comprehensive Cancer Center, California NanoSystems Institute, and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, CA 90095, USA.
^#Equal contribution to this work.

✉ Corresponding author: Zhen Gu (guzhenedu); Ran Mo (rmoedu.cn)

Abstract

Cancer immunotherapy aims to utilize the host immune system to kill cancer cells. Recent representative immunotherapies include T-cell transfer therapies, such as chimeric antigen receptor T cell therapy, antibody-based immunomodulator therapies, such as immune checkpoint blockade therapy, and cytokine therapies. Recently developed therapies leveraging engineered cells for immunotherapy against cancers have been reported to enhance antitumor efficacy while reducing side effects. Such therapies range from biologically, chemically and physically -engineered cells to bioinspired and biomimetic nanomedicines. In this review, advances of engineering cells for cancer immunotherapy are summarized, and prospects of this field are discussed.

Keywords: Cell therapy, Drug delivery, Cancer immunotherapy, Cell engineering, Nanomedicine

Citation styles

©2024 Ivyspring International Publisher. Terms of use